
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc. continues to demonstrate a strong potential for growth as it advances its clinical programs, particularly with rhenium (186Re) obisbemeda, aimed at treating high-unmet-need conditions such as recurrent glioblastoma and leptomeningeal metastases. The positive feedback from the FDA regarding the possibility of an accelerated approval pathway reinforces the therapy's promising profile and illustrates the company's commitment to addressing the substantial demand for new treatments in the oncology space. Additionally, the recent capital raise of approximately $15 million enhances the company's financial stability and operational flexibility, positioning Plus Therapeutics favorably as it prepares for pivotal trials and scales up manufacturing capabilities.
Bears say
The financial outlook for Plus Therapeutics Inc appears negative primarily due to a significant reduction in the 12-month price target from $2.00 to $1.00 per diluted share, reflecting anticipated challenges in market performance. The company's reliance on equity offerings and associated warrants further complicates its financial stability, raising concerns about dilution for existing shareholders. Additionally, the uncertainty surrounding the efficacy of rhenium (186Re) obisbemeda, particularly in comparison to existing treatments and the variability in median overall survival reported in previous studies, contributes to an unfavorable risk assessment for the company's prospects in the oncology market.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares